Osteoimmunity is involved in regulating the balance of bone remodeling and resorption, and
is essential for maintaining normal bone morphology. The interaction between immune cells …

Simple Summary Despite the adoption of aggressive, multimodal treatment schedules, the
cure rate of high-grade osteosarcoma (HGOS) has not significantly improved in the last 30 …

Traditional osteosarcoma therapies tend to focus solely on eradicating residual cancer cells
and often fail to promote local bone regeneration and even inhibit it due to lack of precise …

Osteosarcoma is a quickly developing, malignant cancer of the bone, which is associated
with a bad prognosis. In osteosarcoma, hypoxia promotes the malignant phenotype, which …

Osteosarcoma (OS) is a primary bone cancer that is highly prevalent among adolescents
and adults below the age of 20 years. The prognostic outcome of metastatic OS or relapse is …

Subclassification of tumors based on molecular features may facilitate therapeutic choice
and increase the response rate of cancer patients. However, the highly complex cell origin …

Abstract Background Tyrosine kinase inhibitors (TKIs) such as cabozantinib, regorafenib
have demonstrated encouraging activity in prolonging progression‐free survival (PFS) in …

Bone tumor patients often face the problems with cancer cell residues and bone defects after
the operation. Therefore, researchers have developed many bifunctional scaffolds with both …

Osteosarcoma (OS) is the most common type of bone sarcoma. Despite the availability of
multimodal treatment with surgery and chemotherapy, the clinical results remain …

Hypoxia-induced decrease in cisplatin (CDDP) sensitivity in human osteosarcoma (OS) is a
significant obstacle to effective chemotherapy. Recently, mitophagy has been shown to be …